Taking Profit Out Of ESAs, Insurer Sending Controversial Drugs Directly To Patients.
ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic.
Report Urges Changes To Cut Activation Times For NCI Phase III Trials.
AACR Elects Officers.
Trending Stories
- Mace Rothenberg’s museum will tell the stories behind breakthroughs in medicine
- Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation - Group chairs propose funding strategy to jump-start correlative studies
- 2024 Lasker Awards honor discoveries in antitumor immunity, GLP-1-based drugs, and research, advocacy in HIV/AIDS
- A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease
- Karen Knudsen to leave ACS